Classifying the antibody-negative NMO syndromes
Open Access
- 1 November 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
- Vol. 6 (6), e626
- https://doi.org/10.1212/nxi.0000000000000626
Abstract
Objective To determine whether unsupervised principal component analysis (PCA) of comprehensive clinico-radiologic data can identify phenotypic subgroups within antibody-negative patients with overlapping features of multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSDs), and to validate the phenotypic classifications using high-resolution nuclear magnetic resonance (NMR) plasma metabolomics with inference to underlying pathologies. Methods Forty-one antibody-negative patients were recruited from the Oxford NMO Service. Thirty-six clinico-radiologic parameters, focusing on features known to distinguish NMOSD and MS, were collected to build an unbiased PCA model identifying phenotypic subgroups within antibody-negative patients. Metabolomics data from patients with relapsing-remitting MS (RRMS) (n = 34) and antibody-positive NMOSD (Ab-NMOSD) (aquaporin-4 antibody n = 54, myelin oligodendrocyte glycoprotein antibody n = 20) were used to identify discriminatory plasma metabolites separating RRMS and Ab-NMOSD. Results PCA of the 36 clinico-radiologic parameters revealed 3 phenotypic subgroups within antibody-negative patients: an MS-like subgroup, an NMOSD-like subgroup, and a low brain lesion subgroup. Supervised multivariate analysis of metabolomics data from patients with RRMS and Ab-NMOSD identified myoinositol and formate as the most discriminatory metabolites (both higher in RRMS). Within antibody-negative patients, myoinositol and formate were significantly higher in the MS-like vs NMOSD-like subgroup; myoinositol (mean [SD], 0.0023 [0.0002] vs 0.0019 [0.0003] arbitrary units [AU]; p = 0.041); formate (0.0027 [0.0006] vs 0.0019 [0.0006] AU; p = 0.010) (AU). Conclusions PCA identifies 3 phenotypic subgroups within antibody-negative patients and that the metabolite discriminators of RRMS and Ab-NMOSD suggest that these groupings have some pathogenic meaning. Thus, the identified clinico-radiologic discriminators may provide useful diagnostic clues when seeing antibody-negative patients in the clinic.Keywords
This publication has 43 references indexed in Scilit:
- Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody diseaseActa Neuropathologica Communications, 2017
- Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of responseJournal of Neurology, Neurosurgery & Psychiatry, 2017
- Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosisBrain, 2017
- Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromesZeitschrift für Neurologie, 2015
- Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case seriesZeitschrift für Neurologie, 2015
- Distinction of seropositive NMO spectrum disorder and MS brain lesion distributionNeurology, 2013
- Failure of Natalizumab to Prevent Relapses in Neuromyelitis OpticaArchives of Neurology, 2012
- Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorderMultiple Sclerosis Journal, 2011
- IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrumNeurology, 2010
- Interferon Beta Treatment in Neuromyelitis OpticaArchives of Neurology, 2010